Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49

Benzinga Newsdesk www.benzinga.com Negative 65.2%

Neg 65.2% Neu 0% Pos 0%

Truist Securities analyst Alexander Xenakis maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $58 to $49.